Roivant to Report Financial Results for the Second Quarter Ended September 30, 2024 and Provide Business Update on Tuesday, November 12, 2024
2024年10月30日 - 5:35AM
Roivant (Nasdaq: ROIV) today announced that it will host a live
conference call and webcast at 8:00 a.m. ET on Tuesday, November
12, 2024, to report its financial results for the second quarter
ended September 30, 2024, and provide a business update.
To access the conference call by phone, please
register online using this registration link. The presentation and
webcast details will also be available under “Events &
Presentations” in the Investors section of the Roivant website at
https://investor.roivant.com/news-events/events. The archived
webcast will be available on Roivant’s website after the conference
call.
About Roivant
Roivant is a biopharmaceutical company that aims
to improve the lives of patients by accelerating the development
and commercialization of medicines that matter. Roivant’s pipeline
includes IMVT-1402 and batoclimab, fully human monoclonal
antibodies targeting FcRn in development across several
IgG-mediated autoimmune indications; brepocitinib, a potent small
molecule inhibitor of TYK2 and JAK1 in development for the
treatment of dermatomyositis and non-infectious uveitis; and
mosliciguat, an inhaled soluble sGC activator in development for
pulmonary hypertension associated with interstitial lung disease,
in addition to other clinical stage molecules. We advance our
pipeline by creating nimble subsidiaries or “Vants” to develop and
commercialize our medicines and technologies. Beyond therapeutics,
Roivant also incubates discovery-stage companies and health
technology startups complementary to its biopharmaceutical
business. For more information, www.roivant.com.
Roivant Forward-Looking
Statements
This press release contains forward-looking
statements. Statements in this press release may include statements
that are not historical facts and are considered forward-looking
within the meaning of Section 27A of the Securities Act of 1933, as
amended (the “Securities Act”), and Section 21E of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”), which are
usually identified by the use of words such as “anticipate,”
“believe,” “continue,” “could,” “estimate,” “expect,” “intends,”
“may,” “might,” “plan,” “possible,” “potential,” “predict,”
“project,” “should,” “would” and variations of such words or
similar expressions. The words may identify forward-looking
statements, but the absence of these words does not mean that a
statement is not forward-looking. We intend these forward-looking
statements to be covered by the safe harbor provisions for
forward-looking statements contained in Section 27A of the
Securities Act and Section 21E of the Exchange Act.
Our forward-looking statements include, but are
not limited to, statements regarding our or our management team’s
expectations, hopes, beliefs, intentions or strategies regarding
the future, and statements that are not historical facts, including
statements about potential share repurchases, the clinical and
therapeutic potential of our product candidates, the availability
and success of topline results from our ongoing clinical trials and
any commercial potential of our product candidates following
applicable regulatory approvals. In addition, any statements that
refer to projections, forecasts or other characterizations of
future events or circumstances, including any underlying
assumptions, are forward-looking statements.
Although we believe that our plans, intentions,
expectations and strategies as reflected in or suggested by those
forward-looking statements are reasonable, we can give no assurance
that the plans, intentions, expectations or strategies will be
attained or achieved. Furthermore, actual results may differ
materially from those described in the forward-looking statements
and will be affected by a number of risks, uncertainties and
assumptions, including, but not limited to, those risks set forth
in the Risk Factors section of our filings with the U.S. Securities
and Exchange Commission. Moreover, we operate in a very competitive
and rapidly changing environment in which new risks emerge from
time to time. These forward-looking statements are based upon the
current expectations and beliefs of our management as of the date
of this press release and are subject to certain risks and
uncertainties that could cause actual results to differ materially
from those described in the forward-looking statements. Except as
required by applicable law, we assume no obligation to update
publicly any forward-looking statements, whether as a result of new
information, future events or otherwise.
Contacts:
InvestorsKeyur
Parekhkeyur.parekh@roivant.com
MediaStephanie Leestephanie.lee@roivant.com
Roivant Sciences (NASDAQ:ROIV)
過去 株価チャート
から 11 2024 まで 12 2024
Roivant Sciences (NASDAQ:ROIV)
過去 株価チャート
から 12 2023 まで 12 2024